Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eye Diseases AND Thyroid Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Eye Diseases AND Thyroid Diseases. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-020855-29 Sponsor Protocol Number: E1496/09 Start Date*: 2009-10-16
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI MESSINA
    Full Title: Radioiodine ablation of post-surgical thyroid remnants by recombinant human TSH (rhTSH) in patients with moderately severe and severe Graves' orbithopathy (GO)
    Medical condition: Patients affected with moderately severe and severe GO
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    14.1 10014698 - Endocrine disorders 10043739 Thyroid gland disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005000-36 Sponsor Protocol Number: VGN-TED-301 Start Date*: 2022-07-12
    Sponsor Name:VasaraGen, Inc.
    Full Title: A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)
    Medical condition: Thyroid eye disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10060742 Endocrine ophthalmopathy PT
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.1 10015919 - Eye disorders 10072802 Thyroid associated orbitopathy LLT
    20.1 10015919 - Eye disorders 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000540-15 Sponsor Protocol Number: SPON1266-14 Start Date*: 2014-05-01
    Sponsor Name:Cardiff University
    Full Title: Prostaglandin F2-alpha eye drops (Bimatoprost) in thyroid eye disease: a randomised controlled double blind crossover trial
    Medical condition: Graves' ophthalmopathy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002547-27 Sponsor Protocol Number: OP/CD001 Start Date*: 2005-09-03
    Sponsor Name:University of Bristol
    Full Title: Combined Immunosuppression and Radiotherapy in Thyroid Eye Disease
    Medical condition: Thyroid Eye Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001611-24 Sponsor Protocol Number: CAIN457ADE16 Start Date*: 2021-07-26
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A two-year multi-center Phase 3 study to investigate the efficacy and safety of secukinumab in adult patients with active, moderate to severe thyroid eye disease (ORBIT), with a randomized, paralle...
    Medical condition: Active, moderate to severe thyroid eye disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10060742 Endocrine ophthalmopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002787-68 Sponsor Protocol Number: IMVT-1401-3201 Start Date*: Information not available in EudraCT
    Sponsor Name:Immunovant Sciences, GmbH
    Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004853 10084358 Thyroid eye disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002788-30 Sponsor Protocol Number: IMVT-1401-3202 Start Date*: 2023-07-13
    Sponsor Name:Immunovant Sciences, GmbH
    Full Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10015919 - Eye disorders 10084358 Thyroid eye disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) LV (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003910-33 Sponsor Protocol Number: -- Start Date*: 2007-11-19
    Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS)
    Full Title: Randomized controlled study of rituximab and steroid treatment in thyroid-associeted ophthalmopathy (TAO)
    Medical condition: Thyroid associeted ophthalmopathy.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10015919 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002839-66 Sponsor Protocol Number: IMVT-1401-3203 Start Date*: 2023-09-07
    Sponsor Name:Immunovant Sciences, GmbH
    Full Title: An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004853 10084358 Thyroid eye disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Not Authorised) LV (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006794-37 Sponsor Protocol Number: VRDN-001-101 Start Date*: 2022-05-20
    Sponsor Name:Viridian Therapeutics, Inc.
    Full Title: A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IGF-1 receptor, in normal healthy volunteers (NHVs) and sub...
    Medical condition: Thyroid eye disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004853 10084358 Thyroid eye disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001980-53 Sponsor Protocol Number: GORTX-2012 Start Date*: 2012-05-15
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
    Full Title: Preliminary study on the effectiveness of low doses of Rituximab in patients with Graves’ orbitopathy (GO) poorly responding to immunosuppressive steroid treatment.
    Medical condition: Active moderate to severe Graves Orbitopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10060742 Endocrine ophthalmopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002763-18 Sponsor Protocol Number: HZNP-TEP-301 Start Date*: 2018-02-22
    Sponsor Name:Horizon Therapeutics USA, Inc.
    Full Title: A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Active Thyroid Eye Disease (OPTIC Trial)
    Medical condition: Active Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005999-36 Sponsor Protocol Number: HZNP-TEP-402 Start Date*: 2022-05-24
    Sponsor Name:Horizon Therapeutics U.S.A., Inc.
    Full Title: A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durat...
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004676-35 Sponsor Protocol Number: RVT-1401-2001 Start Date*: 2019-10-23
    Sponsor Name:Immunovant Sciences GmbH
    Full Title: ASCEND GO2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients with Active, Moderate to Severe Graves’ Ophthalmopathy
    Medical condition: Graves´Ophthalmopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002713-58 Sponsor Protocol Number: HZNP-TEP-302 Start Date*: 2018-08-13
    Sponsor Name:Horizon Therapeutics USA, Inc.
    Full Title: Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN.001) Treatment in Subjects with Thyroid Eye Disease
    Medical condition: Thyroid Eye Disease (TED)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001196-20 Sponsor Protocol Number: H2013 Start Date*: 2013-09-24
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO MILANO
    Full Title: PROSPECTIVE STUDY ON THE EFFECTIVENESS OF TWO DIFFERENT DOSES OF INTRAVENOUS METHYLPREDNISOLONE IN THE TREATMENT OF ACUTE DYSTHYROID OPTIC NEUROPATHY
    Medical condition: GRAVES' ORBITOPATHY
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000113-31 Sponsor Protocol Number: TED01RV Start Date*: 2014-07-14
    Sponsor Name:River Vision Development Corporation
    Full Title: A randomized, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks...
    Medical condition: Thyroid-Associated Ophthalmopathy / Graves' Ophthalmopathy
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020482-24 Sponsor Protocol Number: 1 Start Date*: 2014-10-23
    Sponsor Name:Department of Endocrinology, Sahlgrenska University Hospital
    Full Title: Ga-68-DOTATOC -PET in the management of pituitary tumours (PA) and Thyroid associated ophtalmopathy (TAO)
    Medical condition: In this trial with Ga-68 DOTATOC two groupd of patients will be investigated - patients with pituitary adenoma (PA) and patients with thyroid associateed ophtalmopathy (TAO). As the eye muscles and...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000641-41 Sponsor Protocol Number: 2021-000641-41 Start Date*: 2022-01-07
    Sponsor Name:Helse Bergen HF, Haukeland University Hospital
    Full Title: PROSPECTIVE COMPARISON OF SIROLIMUS AGAINST CORTICOSTEROIDS IN TREATMENT OF PATIENTS WITH ACTIVE THYROID EYE DISEASE
    Medical condition: Thyroid Eye Disease (TED) in patients with Graves' Diease.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001158-33 Sponsor Protocol Number: OZR-2016-34 Start Date*: 2017-07-20
    Sponsor Name:The Rotterdam Eye Hospital
    Full Title: A pilot study towards a therapy with prednisolone encapsulated liposomes for the treatment of Graves’ Orbitopathy with reduced systemic steroid exposure
    Medical condition: Graves' Orbitopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 08:31:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA